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Meniscus damage is very common and eventually leads to the deterioration of the entire
knee joint. The goal of this study was to provide evidence that supports a proof of
concept for a decellularized porcine meniscal xenograft to be used as a treatment method
for meniscal injury as a partial or full meniscus transplant. This research adapted an
antigen removal protocol for articular cartilage to produce decellularized xenografts in
48% of the time and with no significant difference in DNA content as other current
methods. DNA and GAG content, and the compression moduli were significantly lower
in the xenograft than the control, but collagen content remained the same. Tensile
modulus and ultimate tensile stress were significantly higher for the xenograft than the
control. Crosslinking analysis was performed and 0.2% genipin was found to have a
significantly higher degree of crosslinking than the rest.
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CHAPTER I
LITERATURE REVIEW
The overall goal of this study was to investigate and determine the ideal meniscus
replacement implant to be used in conjunction with a total meniscectomy. When a
meniscus suffers significant damage due to disease or injury, it eventually leads to the
breakdown of the articular cartilage of the knee. This deterioration of the articular
cartilage leads to the overall deterioration of the whole joint. If the damaged meniscus
could be identified in the early stages of deterioration, it can be resected and replaced by
an implant that would prevent further deterioration. This study first analyses the
meniscus as a whole, its tissue components, role in the functionality of the joint, and the
biomechanical properties of the meniscus. Next, the ways that a meniscus can become
damaged, either through injury or disease, and how these damages are treated is
described and assessed. Finally, this study evaluates the current implant types in
development and recommends the most ideal choice of implant.
The Meniscus
The meniscus is a crescent, or “C” shaped cartilaginous tissue in the knee joint. It
is comprised of a lateral and a medial component and is situated between the femoral
condyles and the tibial plateau. The main functions of the meniscus are to act as a loadbearer, shock absorber, to evenly distributing load transmission through the knee joint,
and to provide lubrication and nutrition to the articular cartilage of the femur and tibia1.
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Anatomical Review
The “C” shape of the meniscus provides the effective coverage and protection for
the articular cartilage of the femur and tibia while leaving the innermost portion of the
knee joint, between the femoral condyles, exposed. It is in that exposed region where the
insertion and origin points for cruciate ligaments, the main stabilizing ligaments of the
knee, are located.

Figure 1.1

Superior view of the knee and menisci.6

The menisci are wedge shaped with concave proximal surfaces that are aligned
directly inferior to the lateral and medial condyles of the femur. The articular cartilage of
the femur rests directly on the proximal surface of the meniscus. The distal surface of the
meniscus is flat and lies superior to the articular surfaces of the lateral and medial
condyles of the head of the tibia. The menisci are connected to the tibial plateau by the
horn attachments on the anterior and posterior horns of the crescent. The anterior horn is
2

attached anteriorly to the anterior cruciate ligament (ACL) and the posterior horn is
attached anteriorly to the posterior cruciate ligament (PCL).
Comparing the two menisci, the lateral meniscus is larger, has more variation in
size, and covers more of the tibial plateau than the medial meniscus2,3,4,5. The lateral
meniscus also has more ligament connections than the medial meniscus. The anterior and
posterior horns of the lateral meniscus are connected by the transverse (intermeniscal)
ligament. The posterior horn has three additional connections, the first two being
connections to the PCL and medial condyle of the femur by the meniscofemoral
ligaments of Wrisberg, posteriorly to the PCL, and Humprey, anteriorly to the PCL. The
third connection is to the popliteal tendon which can act on the posterior horn and move
the lateral meniscus during flexion6. The medial meniscus lacks any attachment to the
corresponding lateral cruciate ligament but does have an additional attachment to the tibia
via the coronary ligament7.
Biochemical Content
Meniscus tissue is very hydrated, with 72% of the weight being water. The
remaining 28% of the wet weight is fibroblast cells in an extracellular matrix (ECM)
composed of collagen, proteoglycans, DNA, adhesion glycoproteins, and elastin8,9. The
main types of collagen found in meniscus tissue are type I and type II collagen. There are
also trace amounts of types III, IV, VI, and XVIII collagen and elastin found in different
regions of the meniscus tissue10. Aggrecan is the main large proteoglycan molecule in
meniscus tissue and biglycan and decorin are the main smaller proteoglycan molecules11.
Proteoglycan molecules are extremely important to the functionality of the meniscus.
Structurally, proteoglycans have heavily branched and negatively charged
3

glycosaminoglycan (GAG) molecules bound to a core protein. The negative charges on
the heavily branched regions attract water into the meniscus, maintaining the tissue’s
hydration, the visco-elastic behavior, compressive stiffness, and surface friction reduction
of the tissue12,13.
Zones of the Meniscus
The meniscus has two main zones, the outer zone and the inner zone, with regards
to collagen content. The collagen fibers change in orientation and type moving from the
most superficial layer inwards. There is also an increase in the concentration of
proteoglycans toward the center of the meniscus14.
The outer zone of the meniscus is characterized by an ECM comprised of mostly
type I collagen and small concentrations of GAGs. The chondrocytes in the outer zone
are oval and fusiform15. These chondrocytes produce the ECM and lay the type I
collagen circumferentially along the “C” shape of the meniscus. There are two distinct
layers of collagen, the superficial and surface layers, found in the outer zone.
The inner zone of the meniscus is categorized by an ECM composed from mostly
type II collagen, with a smaller but significant percent of type I collagen, and a higher
concentration of GAGs. The chondrocytes in the inner zone are more round than the
chondrocytes of the outer zone and produce an ECM that includes the circumferential
pattern of the type I collagen with the addition of radially arranged collagen to resist
longitudinal splitting16,6.
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Figure 1.2

Collagen orientation creates and inner and outer zone of the meniscus.91

The meniscus can also described by zones of vascularity. The peripheral
meniscus is vascularized by the geniculate arteries through the anterior and posterior horn
attachments17. The peripheral rim of the meniscus, termed the “red-red zone”, is the most
vascularized zone with up to 30% vascularity. This percentage continuously decreases
with age until the inner two thirds of the menisci are completely avascular7. The middle
zone is called the “red-white zone” because some vascular tissue is able to penetrate
deeper into the meniscus tissue. The most central zone of the meniscus is called the
“white-white zone” and is totally avascular, receiving nutrition through synovial fluid
diffusion18.

5

Figure 1.3

The vascular zones of the meniscus.

The differing vascularities throughout the meniscus have a significant effect on
the healing rates of injured meniscus. Areas with higher vascularity have better repair
and healing potential than lower or avascular areas14.
Biomechanical Properties
The knee joint is a highly active, load bearing joint that exerts a variety of
dynamic forces on the meniscus. The meniscus withstands shear, tension, and
compressive forces during flexion, extension, and load bearing1. The wedge-shape of the
meniscus allows for these forces to be stabilized between the curved femoral condyles
and the flat surface of the tibial head. The wedge-shape effectively converts the vertical
compressive forces exerted on the meniscus from the femur into hoop stress that is
contained as tension within the meniscus. Shear forces develop between the collagen
fibers as the meniscus is deformed radially by compression19,20,21.
Values for these forces have been calculated and documented in many studies.
The shear forces on the meniscus is approximately 120 kPa22. The tensile properties of
the meniscus are significantly different depending on the direction of the tensile force.
The circumferential tensile strength is approximately 100-300 MPa, while the radial
tensile strength is approximately 10-30 MPa. The meniscus resists axial compression
6

with an approximate stress of 100-150 kPa23. The meniscus occupies 60% of the contact
area between the femoral and tibial articular cartilage and transmits over 50% of the
compression forces on the joint at full extension and 85% of the load at 90̊ of flexion24,25.
Meniscus Injury
Knee injuries, with meniscal lesions in particular, are the most common injuries
requiring surgical intervention in the United States26,27,28. These injuries usually occur
during sports or sports-related activities that involve cutting and twisting movements,
hyperextensions, or high impact4. The most common motion that causes a tear in the
meniscus is an internal rotation of the femur as the knee moves from a flexed to an
extended position, splitting the meniscus longitudinally6. Trauma induced meniscal
injury usually occurs in conjunction with anterior cruciate ligament tearing, occurring in
>80% of cases, and is more common in the medial meniscus1.
Tear Classification
Classification of meniscal tears is determined by location and tear pattern. Tears
can be denoted by the vascular region in which they occur. Tears in the peripheral
attachment sites, either meniscofemoral or meniscotibial, are called red-red tears. Tears
located in the middle zone are called red-white tears. These tears typically occur at the
junction of the red-red zone and the red-white zone, approximately 4mm from the
meniscal attachment. The inner most zonal tears in the avascular region are called whitewhite tears1. Classifying tears due to their vascular zone is important because the healing
potential is significantly different in the different regions. A red-red tear has a much
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greater chance of healing naturally than a white-white tear, which almost always requires
surgical repair.
Tear Patterns
There are five types of tear patterns for meniscal lesions caused by traumatic
injury and a specific tear pattern for gradual degeneration. The five tears caused by
traumatic injury can either be partial or full tears of the tissue, with partially torn tissue
having a greater healing potential than fully torn tissue.

Figure 1.4

Visual representations of the different types of meniscal tears.6

Radial tears occur perpendicular to the circumferentially oriented collagen and
often occur along with ACL injury. Longitudinal tears run along circumferentially
oriented collagen fibers along the length of the meniscus. A bucket-handle tear is a full
depth longitudinal tear that causes additional problems because it creates a long segment
of the meniscus that has separated from the main body of the meniscus. This segment,
which resembles a “bucket handle”, can get caught on the medial side of the femoral
condyle and cause joint locking. Horizontal tears form in the body of the meniscus and
eventually bisect the tissue into a superior portion and an inferior portion. These tears are
difficult to identify and are even more difficult to repair. Flap tears are horizontal tears
that occur in a close proximity to the surface and cause a flap of the surface tissue to open
8

and close with movement. Complex tears occur when there are multiple tears in multiple
planes. These types of tears are difficult to repair and are commonly found in
degenerative cases. Complex tears are normally too damaged to repair and require a
meniscectomy6.
Degenerative injury causes a specific tear pattern, referred to as a degenerative
tear, and is characterized by a frayed edge appearance of the medial portion of the
meniscus. Meniscal lesions that develop as a result of gradual degeneration usually
appear in tandem with other degenerative problems in the knee. These types of tears are
very common, especially in subjects with knee pain or osteoarthritis. One study of
patients over the age of 65 found that 91% of patients with symptomatic osteoarthritis
had degenerative tears29. The study also found that 67% of patients who were
asymptomatic for knee pain also had degenerative tears. Because these tears occur in the
medial zone of the meniscus, they are entirely in the white-white zone and have almost
no healing capability. The only treatment option for degenerative tears is a partial or full
meniscectomy. The high prevalence of degenerative tears in the population combined
with the only treatment option being a meniscectomy, means that there is a large demand
for an effective meniscus implant.
Diagnosis
A comprehensive examination is required in order to diagnose a meniscal tear.
Tibiofemoral joint-line tenderness is the primary indicator of a meniscal tear24.
Symptoms of joint tenderness include joint stiffness, swelling, pain, lack of full
extension, and deformity. The assessment of the tibiofemoral joint line is performed with
the patient lying on a flat surface with the knee positioned at a 90̊ flexion.
9

Osteoarthritis
The primary long term consequence of meniscal injury is the development of
osteoarthritis in the knee joint. Osteoarthritis (OA) is the most common degenerative
joint disease that affects more than 25% of the adult population30. Symptoms of OA
include chronic pain, joint instability, and stiffness. This is due to a progressive loss and
destruction of articular cartilage, thickening of the subchondral bone in response to
greater shear forces on the bone, formation of bone spurs in the joint, significant increase
in inflammation in the synovial cavity, and a degeneration of the ligaments and meniscus
leading to a narrowing of the joint space31. There is significant data that supports that
past meniscus injury has a strong correlation to the prevalence of OA32. A study of
former NFL athletes found that athletes with a history of meniscal repair were almost 3
times more likely to develop OA, and that players who underwent a partial meniscectomy
were 6 times more likely to develop OA33. Other factors that contribute to the
development of OA include obesity, aging, and heredity34.
The molecular mechanisms that facilitate the start and progression of OA are not
well understood and there are currently no known treatments to restore degraded cartilage
or stop the progression of the disease30. Nonsurgical treatment of OA is limited to antiinflammatory drugs including NSAIDs and hyaluronic acid or corticosteroid
injections35,36. Once the disease progresses to include severe articular cartilage damage
and bone fragmentation, surgical intervention is needed. Arthroscopic surgery can be
performed to remove rough edges and bone fragments in the joint, but more severe cases
require a more invasive option. An osteotomy can be performed to remove a severely
damaged portion of either the tibia or the femur to relieve pressure on the joint. An
10

osteotomy will only delay the need for a total knee arthroplasty, the eventual end
treatment for OA. The degradation of the joint will eventually become so severe that a
partial or total knee replacement will need to be performed. The surgically reconstructed
joint is made of metal, plastic, or combination of the two and is anchored into the shafts
of tibia and femur after the diseased tissue has been removed37,38.
Treatment Options
There are three main treatment options for a meniscus tear: surgical repair,
meniscectomy, and meniscus replacement. In order to determine the proper course of
treatment, an arthroscopic survey and MRI scan of the tissue is performed. The course of
treatment is dependent on the location and the severity of the tear, as well as the age and
overall health of the patient. The end goal of the treatment option chosen is to delay the
onset of OA for as long as possible if not indefinitely. Some tears do not require surgical
intervention. These tears are typically red-red tears and tears smaller than 8mm that have
minimal damage to the main body of the meniscus6. Because these tears occur in the
vascularized region, their potential for healing is far greater.
Surgical Repair
Meniscus tears that are good candidates for meniscal repair are unstable red-white
tears that are longer than 10-12mm in active patients under the age of 5024,25. Typical
tear patterns that have higher success rates of repair are longitudinal, radial, or buckethandle tears39. Longitudinal tears are generally the most successful with nearly an 85%
healing rate40. Longitudinal tears are caused by excessive compression and tear the
meniscus along the circumferential collagen fibers, which remain intact. These fibers are
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vital in the strength and force dissipation of the meniscus. Suturing these back together,
most closely resembles an uninjured tissue, which leads to the high rates of success41.
There are two main types of meniscal surgical repair, arthroscopic and open repair.
Arthroscopic Repair
There are three techniques that can be used during an arthroscopic repair of a
meniscus tear, inside-out, outside-in, and all-inside39. The inside-out and the outside-in
techniques require a 2.5-4cm accessory posteromedial or posterolateral incision for suture
retrieval. The all-inside technique is completely arthroscopic and does not require an
incision25. In all surgeries, the meniscus is prepared by performing a granulation tissue
debridement with a meniscal rasp on the edges of the meniscal tear and perimeniscal
tissue surrounding the tear42. This increases the vascular infiltration to the tear and in the
adjacent tissue that significantly aids in the healing process.
The inside-out technique is the considered the gold standard classical technique
for meniscus repair42. The technique is very versatile, with the ability to repair most tear
patterns, and allows for the use of smaller diameter needles. The disadvantages of the
inside-out technique include an increased risk of neurovascular injury to the popliteal
vessels, an increased surgical time, post-operative pain, necessity for a surgical incision,
and needlestick injury to the surgeon. Using a cannula to guide a long needle, the sutures
are started from within the meniscus and pass through the tissue toward posterior. On
each pass, the needle exits either through the posteromedial or posterolateral incision so
another throw can be initiated43. Once complete the sutures are tied over the capsules on
the periphery of the meniscus.
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The outside-in technique is typically only used for longitudinal tears of the
anterior horn of the meniscus because there is limited arthroscopic access in the region40.
Tears are sutured with spinal needles that are pushed through the outer rim of the
meniscus and then through the torn fragment. One main advantage of this technique is
the ability to avoid neurovascular injury of the surrounding tissue without creating a large
posterior incision18. The two main disadvantages of this technique is the use of larger
diameter needles, which cause more damage when passed through the body of the
meniscus, and difficulty of tying perpendicular sutures in tears adjacent to the posterior
horn attachment.
The all-inside technique is a completely arthroscopic procedure characterized by
the use of bioabsorbable repair devices including arrows, screws, darts, and staples
instead of sutures18. Currently the most frequently used devices are suture-like anchors
that are fixed to the meniscus fragments and then connected using a polyester
nonabsorbable suture. These anchors can be oriented many different ways and thus can
repair many types of tears. All-inside repairs are becoming more popular because the
procedure does not require the need of an accessory incision and has a shorter surgical
time42. The all-inside technique has significantly developed since its invention in 1991,
but historically some of the devices have been found to be mechanically inferior to
sutures18,44. The newer suture-like anchors have shown to be comparable to the sutures
used in the inside-out technique in strength, flexibility, and load-to-failure42,18.
Open Repair
Open repair was the original method of meniscal repair. This technique requires a
20-30cm incision, through tendon and muscle, to visualize the entire joint. Vertical
13

sutures are usually used to repair any tears39. Due to the size of the incision, there is a 3
month recovery along with increased risk of infection, blood clotting within the joint, and
further cartilage damage. Open repairs have become less and less common as
arthroscopic techniques have developed, but they are performed when the medial
compartment is too tight or if the knee is already opened for a separate procedure40.
Meniscectomy
In cases with more significant meniscal damage or a white-white tear, surgical
repair is not recommended and a partial meniscectomy is performed. In a meniscectomy,
the overly damaged portion of the meniscus is resected, leaving the healthy portions to
maintain the function of the knee joint and compensate for the missing portion. A partial
meniscectomy is also the recommended treatment option for patients over 50, sedentary
patients, or patients unwilling to comply with the rehabilitation procedures required after
a meniscal surgical repair. Complex tears and degenerative tears must be treated via
partial meniscectomy, making it the most commonly performed surgical treatment for a
meniscal tear45. Horizontal tears, caused by excessive shear forces, are usually
degenerative and must also be removed with a partial meniscectomy46. Partial
meniscectomies speed up the progression of OA within the knee joint and are generally
only performed on older patients. However, due to the shorter rehabilitation period of a
partial meniscectomy, it is often chosen over a meniscal repair by competitive athletes
who wish to resume training as soon as possible12.

14

Meniscus Replacement
Due to the significant correlation of early OA development with meniscal repair
and partial meniscectomy, alternative methods to replace rather than repair the meniscus
have been investigated. Replacing the damaged meniscus with healthy tissue or tissue
substitute would prevent further damage to the articular cartilage and potentially halt the
onset of OA. The advancement of tissue engineering has allowed for the development of
tissue or tissue-like scaffolds that mimic the collagenous framework of the native
meniscus tissue. These scaffolds can then either be populated by chondrocytes, creating
a living tissue implant, or promote healing and regeneration of the host tissue within the
scaffold. The scaffold is then implanted into the patient as a functional, biologically
active transplant. The development of tissue engineering has been so significant that
there are now several different methods to custom design a fully functioning scaffold to
fit to a patient’s knee1,47.
There are two general types of tissue engineered scaffolds, categorized by the
amount of the damaged meniscus initially removed. The first type of tissue engineered
scaffolds is designed for partial meniscectomies. These scaffolds are designed to
integrate fully into the host tissue and facilitate the reconstruction of the meniscal tissue.
Due to the widespread use of partial meniscectomy, meniscus reconstruction scaffolds
have increasingly become in demand. After removing the damaged meniscus tissue, a
custom-sized scaffold is fitted and sutured to the body of the original meniscus48. As the
injury heals, the highly porous scaffold facilitates the regeneration of meniscus-like tissue
to infiltrate and eventually replace the scaffold with native tissue49. Short and long term
studies have both shown that the reconstruction implants have improve knee function,
15

pain reduction, and restoration of activity levels49,50,51. Generally, meniscus
reconstructions are more effective for trauma induced meniscal tears, rather than
degenerative or complex tears.
The second type of tissue engineered scaffolds is a total meniscus replacement
scaffold. When the damage to the meniscus is too great or the meniscus is riddled with
degenerative tears, a total meniscectomy of the body of the meniscus should be
performed. Because there is none of the body of the host meniscus remaining, the full
replacement must be able to perform all of the mechanical functionalities of a meniscus
upon implantation, while promoting cellular migration to eventually allow the graft to
perform all of the biological functionalities as well. The total replacement also needs to
promote host tissue integration from the remaining vascular peripheral tissue to fully be
assimilated as a transplant. Clinical evidence shows that total meniscus allograft
transplantations (MAT) have proven to be very successful treatment methods for
meniscus repair.52
Cell Sources for Tissue Engineering
One trait that all tissue engineered scaffolds have in common is that the final
product of implant production and processing is acellular. An effective acellular implant
must allow for the host to facilitate healing and integration via cellular migration and
vascularization. This can either be achieved by the host after the implantation of a
decellularized scaffold or the scaffold can be pre-seeded with cells before transplantation.
Cell compatibility is a major concern because any cell, protein, or enzyme that is seen as
foreign will trigger an immune response and cause the scaffold to be rejected. Cell
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sources are assessed by their immune response limitation and the availability of healthy
cells.
Autologous Chondrocytes
Autologous chondrocytes are the obvious first cell source to investigate because
they are directly collected from the patient and there is no need for additional processing
of the cells. The main drawback for autologous chondrocytes is cell availability. In
order to collect cells for the autologous chondrocyte implantation (ACI), a pre-transplant
surgery must be performed to gather thin slices of cartilage from minor weight bearing
areas of the joint1,53. This allows for the maximum amount of chondrocytes to be
harvested while minimizing the trauma to the joint. The number of cells harvested is
limited because the ratio of chondrocytes to collagenous ECM in a meniscus is extremely
small and the cells producing the desired GAG matrix located only within the inner
collagenous zone of the meniscus54,55,56. This small number of cells can be expanded via
a monolayer culture. However, this monolayer causes the cells to differentiate into the
chondrocyte morphology found in the outer collagenous zone which have a significant
downregulation of ECM gene expression, causing them to produce less ECM matrix with
the desired GAGs57. Another concern with using autologous cells is the possibility of
cells already being in a diseased state due to OA58. Once in the diseased state, the
chondrocytes will continue to break down the articular cartilage in the joint as well as an
implanted scaffold.
Recent studies of chondrocytes in articular cartilage, which also dedifferentiate
when proliferated in a monolayer culture, show that the cells can redifferentiate using a
3D pellet model59. The study was performed with OA chondrocytes as well and showed
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that after redifferentiation, the cells began exhibiting normal chondrocyte expression.
Although this research shows that more viable differentiated cells can be produced, the
use of autologous cells is still restricted in clinical practice due to their high cost to
collect and prepare.
Allogenic Chondrocytes
In an attempt to avoid the complications that have risen with using autologous
cells, researchers have looked to allogenic cells as a cell source for tissue engineering
meniscus scaffolds. Research has shown that allogenic cells are equally effective as
autologous cells in functionality and promotion of healing of meniscal lesions60.
Benefits of allogenic cells are that they can be harvested from cadavers in greater number
than autologous sources because the entire tissue can be resected and used. Also, the host
immune response to allogenic cells is very limited due to the low vascularity in the region
and the dense ECM that surrounds the allogenic cells56. Even though meniscus tissue is
deemed “immune-privileged”, there have been studies that have shown that over time the
summation of the limited immune responses from allogenic cells can lead to the overall
destruction of the tissue by macrophages, natural killer cells, and T cells61.
Drawbacks to allogenic cells include possible disease transmission and
availability. Even though allogenic cells can be collected in greater number than
autologous cells, the availability of cadaver sources with healthy fresh cells is still
limited. There are also limitations with the methods of cryogenically preserving or
storing cells in a refrigerated state for a prolonged time. Both storage methods has been
shown to reduce the viability, effectiveness, and metabolism of the chondrocytes62.
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Xenogeneic Chondrocytes
The main drawback of autologous and allogeneic cell sources is cell availability.
Xenogeneic cell sources have the potential to provide for the high demand for
chondrocytes to reseed scaffolds and repair lesions. However, using a xenogeneic source
of cells has a major drawback in that it generates an immune response from the host. A
recent study suggests that that the immune response can be prevented by removing the
cellular and molecular mechanisms that trigger an immune response through genetic
engineering53. This study identified the molecular targets of the human immune system
on pig chondrocytes and the pathways of rejection for each target. With the molecular
targets and immune system pathways identified, the pig chondrocytes can be genetically
engineered to not express these targets and thus avoid the immune response. Researchers
have already shown that this can be plausible by using homologous recombination and
vector cloning to eliminate the expression of the carbohydrate antigen Gal, a common
target against pig tissue by a humoral immune response63. Pig tissue is considered to be
the best source for xenogeneic cells and tissues because it is domesticated, easily
reproducible in large qualities, and has similar physiology and size of cells and tissues to
humans53.
Mesenchymal Stem Cells
Another more recent source of cells that has been researched is the adult
mesenchymal stem cells (MSC). MSCs are desirable because they naturally have the
ability to differentiate into chondrocytes64. These cells can be found in bone marrow,
adipose tissue, synovium, periosteum, skeletal muscle, skin, amniotic fluid, or umbilical
cord blood65. Both autologous and allogenic MSCs can be used in research due to their
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immunomodulary characteristics66. Allogenic MSCs are a promising avenue because
patients receiving allogenic MSCs only undergo one surgical treatment instead of the two
needed to use autologous MSCs. Research shows that both types of MSCs can be either
seeded in a scaffold or injected into the lesion to promote healing and/or tissue
integration by the host65,67.
A major concern when using MSCs is triggering proper chondrogenesis and
differentiation. In order to trigger MSC chondrogenesis there must be a high cellular
density with a biological environment stimulated by growth factors68. Proper MSC
differentiation is driven by a combination of biological and mechanical factors which
interact to ensure that the correct cellular differentiation is happening in the correct areas
of the meniscus1. Growth factors play a vital role in differentiation, but the mechanical
stresses to which the cells are exposed also has an impact on cellular differentiation.
Properly differentiated chondrocytes are important because they need to be producing the
correct ECM matrix that mirrors and integrates with the native tissue surrounding it. The
wrong ECM matrix in the wrong area will not be able to maintain the biomechanical
functionality of the tissue.
Types of Meniscus Scaffolds
There are four main classes of meniscus scaffold implants: synthetic polymers,
hydrogels, ECM components, and tissue grafts1. These classes are based on the method
of construction, how the tissue is processed, and the material used to create it. The
classes are not mutually exclusive and some researchers have experimented with hybrid
combinations of different materials in order design the best model scaffold. A successful
scaffold should restore the functionality of the knee (mechanically and biologically),
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allow for host tissue integration, degrade once the host tissue has regenerated, and have
the ability to be replicated successfully and cost effectively on a large scale.
Synthetic Polymer Implants
Synthetic polymer scaffolds are created from durable polymers not normally
found in the body but that also are nontoxic and biodegradable. Synthetic scaffolds
generally excel at replicating the mechanical functions of the meniscus1. The most
common types of synthetic scaffold are polyurethane (PU), polycaprolactone (PCL),
polylactic acid (PLA), polyglycolic acid (PGA), and polylactic co-glycolic acid (PLGA).
These synthetic scaffolds benefit from being able to be fabricated by a variety of different
methods, have an almost unlimited supply, and they can be specifically designed to create
specific pore sizes and fiber thicknesses to customize the mechanical properties of the
scaffold.
The main weakness of synthetic scaffolds is that they have little to no biological
activity. This has lead synthetic scaffolds to be designed to maximize the host’s
regenerative potential to occur within the scaffold’s framework. With this design,
synthetic scaffolds have been effectively used as partial meniscus reconstructions.
Actifit® (Orteq Biologics, London UK) is one of the most successful synthetic meniscus
implants on the market. The Actifit® is a honeycomb polyurethane scaffold that
provides the maximum space for host tissue reintegration, while still maintaining the
minimum mechanical function needed until the host tissue can begin to reassume the
function69. This minimum level, however, does not provide the load support equivalent
to a native meniscus as it only serves to act as scaffolding for new tissue regeneration.
Studies have shown that Actifit® excels as a partial meniscus reconstruction, with tissue
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reintegration and significant improvement in knee functionality in almost all of the
patients tested70. However, due to the biological inactivity of the polyurethane and the
inability to provide load support equivalent to the native tissue, the Actifit® implant
would not be a sufficient total meniscus replacement. The Actifit® implant does prove
that an acellular scaffold can be used to regenerate a large portion of the meniscus
without having to pre-seed cells directly into the transplant.
Synthetic scaffolds have a place as treatments for partial meniscus reconstructions
after a partial meniscectomy. But the biological inactivity and structural weakness of the
scaffold prevents its usage as a total meniscus replacement. In order to create a viable
synthetic scaffold for total meniscus replacement, a synthetic material or a composite of
synthetic and more biologically active material that could provide better structural
support would need to be investigated.
Hydrogel Implants
Hydrogel scaffolds were a result of researchers attempting to create a biologically
active meniscus scaffold that most closely resembles the molecular environment of native
tissue. Hydrogels have a very high water content, much like native meniscus tissue, and
have the ability to have chondrocytes and growth factors seeded directly into the scaffold
during creation71,72. Hydrogels can be created from synthetic materials or natural
components, but the most successful have been made from collagen. Collagen is
preferred because it is the main structural component of meniscus tissue leading to a high
biocompatibility, is readily available, and scaffold formation can be controlled with pH
and temperature71,73,74. Collagen based hydrogels are made from dissolving collagen in
acid which then are allowed to reassemble into a triple helix structure. These types of
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collagen hydrogens have been developed for partial meniscus reconstruction as an
implantable scaffold or an injectable ECM hydrogel75,76.
The main drawback with hydrogels is their weak mechanical properties. Without
modification, hydrogels are unable to withstand the physical and mechanical demands of
the tissue and are very difficult to be handled in a clinical setting71. There is also an
overall shrinking of the scaffold once cells are seeded due to cell-collagen interactions.
This leads to a reduced overall size and shape of the scaffold, limiting the scaffolds
ability to mimic the native tissue precisely.
In order to overcome the mechanical disadvantages, hydrogels have been
supplemented with collagen crosslinkers that significantly increase the stability and
mechanical properties of the scaffold. Traditional crosslinkers include glutaraldehyde
and formaldehyde, but these chemicals are extremely cytotoxic. Researchers have
investigated and found success with less cytotoxic crosslinkers like genipin,
epigallocatechin-3-gallate (EGCG), and photo-induced crosslinking with riboflavin77,78,75.
There are several ongoing studies aimed at finding the best balance between mechanical
strength and functionality while minimizing cytotoxicity to optimize the potential for
hydrogel scaffolds.
Another significant drawback with hydrogels is the difficulty of promoting proper
cell differentiation in the scaffold and inducing ECM synthesis1. Cells tend to be uniform
throughout the matrix, and not vary with location as found in natural tissue. This causes
ECM production and tissue regeneration to be biologically different than native tissue.
Researchers have attempted to use cellular adhesion to help promote correct cellular
morphology within hydrogels to address this issue79.
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Hydrogels tend to have many more drawbacks than advantages. The high
biocompatibility and close-to-natural cellular environment is countered by the difficulty
of promoting proper cellular morphology and ECM production. The structural weakness
of the tissue can be supplemented with collage crosslinking making hydrogels potentially
effective for partial meniscus reconstruction. A significant structural weakness of
injectable hydrogels is that there is currently no way to mold the scaffold into any
particular shape. Injectable hydrogels could be very successful in filling lesions or
resected areas with structural boundaries to hold the hydrogel in place, but they cannot be
used for a total replacement. The geometry of the meniscus is too important to the
function in the knee joint to not have proper means of shaping or designing it. The
combination of inefficient cell differentiation, improper ECM deposition, and mechanical
weaknesses, even with crosslinking supplementation, it is not recommend for hydrogels
to be used as total meniscus replacements.
ECM Component Implants
ECM component implants are characterized by the fact that they are constructed
mainly with macromolecules commonly found in the native meniscus matrix. The most
common ECM component implants are made from collagen or hyaluronic acid. Collagen
scaffolds have been the most successful. Collagen scaffolds can be created via several
manufacturing methods and have strength comparable to synthetic scaffold1. In terms of
bioactivity, collagen scaffolds can create an effective natural environment for seeded
cells much more effectively than synthetic scaffolds and hydrogels. The cellular
microenvironments are not exactly identical to the natural tissue, but seeded MSCs in
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acellular CMIs have been shown to still be able to produce significant amounts of
fibrocartilaginous ECM that integrated with the host tissue80.
The first ECM component implant cleared for usage in human patients was a
collagen meniscus implant (CMI) called Menaflex®. This CMI is made of bovine
Achilles tendon type I collagen and has proven effective at alleviating pain and restoring
normal knee function and physical activity along with host tissue integration14,81,82,83,84.
Disadvantages with the Menaflex® is that the use of bovine collagen carries the risk of
disease transmission and possible immunogenic reaction85. Another disadvantage is that
once the CMI is moistened, it becomes very fragile, making the surgical procedure much
more difficult69. ECM scaffolds in general tend to have poor cellular infiltration which
can make seeding the scaffold difficult76.
ECM scaffolds are successful because they strive to be as identical to native
meniscus tissue as possible. Structurally they provide mechanical stability and
functionality comparable to native tissue. The cellular environments of ECM scaffolds
are biologically active and closely resemble native tissue, allowing for proper cellular
differentiation and ECM production. ECM scaffolds have been used as partial meniscus
reconstructions and also have the potential to be used as a total meniscus replacement.
Tissue Graft Implants
The final category of meniscus scaffolds are tissue grafts. The ideology behind
the first three categories, synthetic, hydrogel, and ECM scaffolds, is an attempt to
completely recreate meniscus tissue, in form and function, from various materials
through tissue engineering. Mimicking the natural tissue has proven to be difficult due to
the subtle differences in collagen content/ orientation and properly dispersed and
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differentiated chondrocytes. The ideology of using tissue graft implants is different in
that it seeks to use tissue engineering to convert natural meniscus tissue, which is already
properly structured, into an acellular implant that can be reseeded with chondrocytes
compatible with the host86. This alleviates the structural and biocompatibility issues
faced by other grafts, but it also creates some unique challenges in creating the implant.
There are two types of tissue grafts that can be used to create an acellular scaffold,
categorized by their original donor. Allografts are collected from human cadavers and
xenografts are harvested from anatomically similar species of animal. Both types of
grafts are processed similarly and must be decellularized. Decellularization is a process
in which all cellular components of the past host are removed to prevent an immunogenic
response to the new tissue once implanted. There are several methods of
decellularization, but generally the cells within the graft are forced to burst by freezing or
submersion in either a detergent or a hypotonic solution87,88. Then the cellular
components are either washed away or digested using DNase and RNase enzymatic
activity. The resulting acellular tissue is mechanically weakened through the
decellularization process, but this can be countered with the addition of collagen
crosslinking to add stability to the tissue88,77. The end product is a structurally sound
acellular implant.
Allografts at face value seem like the most logical candidate to create a tissue
derived scaffold. Ideally it would be a like-for-like change between the donor and host.
Originally, allograft menisci were used as a direct transplant and cellular survival was
extremely important and various methods of cryopreservation or fresh-frozen protocols
were investigated89. These transplants had high failure rates due to the preservation
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methods killing cells so decellularized allograft scaffolds have become the preferred
method88.
An implication that should be noted for allografts is the possibility for disease
transmission. This was more of a disadvantage when allografts were being used as a
direct transplantation. The decellularization and sterilization techniques that would
normally be used to create a safe allograft scaffold would prevent disease transmission.
Allograft scaffolds are definitely capable of providing a successful treatment for a
partial meniscus reconstruction and a total meniscus replacement. The main disadvantage
with allograft scaffolds is tissue availability80. With the high incidence of OA in older
patients, finding a cadaver with an intact and healthy meniscus can be difficult. This
problem is further compounded by the need to size match the donor to the recipient. This
causes allograft scaffold creation to very expensive and not an ideal candidate for
widespread use of meniscus replacement.
Immunogenic rejection has traditionally prevented the use of xenografts as a
transplantable tissue source. Advancement in decellularization techniques has led to the
serious possibility of using a xenograft meniscus as a meniscus scaffold. Because the
decellularization process removes all traces of cellular material, there is nothing for the
host’s immune system to generate an immune response to. One key area that needs to be
addressed with xenografts is the anatomical differences between the donor species and
humans. In a partial meniscus reconstruction, the anatomical difference would not make
a significant impact because the desired portion can be cut from the xenograft. In a full
meniscal replacement, the anatomical differences could be very significant. Studies on
the anatomical similarities between humans and animals have shown that pigs, goats, and
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cows have menisci that would be anatomically suitable for usage by humans90. The
attachment sites are the main anatomical differences in the animal menisci. However,
this issue can be solved by designing and applying appropriate attachment sites during
creation of the scaffold so they can be easily attached during implantation.
A xenograft scaffold implant is a versatile treatment method for a partial meniscus
reconstruction and the most promising treatment option for a total meniscus replacement.
The framework of the collagen fibers from the tissue graft is already properly oriented to
encourage the development of proper cell morphology within the scaffold. This allows
the cells to produce the appropriate microenvironment and ECM matrix to begin the
regeneration and host integration process. The availability of xenograft meniscus tissue
is almost unlimited, especially with porcine tissue, and decellularized scaffolds can be
frozen and stored91. This allows for large scale production of scaffolds to accommodate
the large need for meniscus reconstruction and replacement. In terms of cost,
availability, and functionality, a xenograft derived scaffold would be the best direction
for researchers to develop as the main treatment for a total meniscus replacement.
Conclusion
There is a great need for the development of a reliable and effective total
meniscus replacement. This is due to the great number of knee related surgeries
performed each year and the high prevalence of OA in the population. While meniscus
repair surgeries have proven effected in repairing the tissue, only minor tears can be
repaired and further complications develop that eventually lead to a heightened
development of OA and joint instability. Total meniscus replacement can be a viable
option that replaces not only severely damaged tissue but also previously repaired
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meniscus tissue before the onset of OA. A xenograft tissue based meniscus scaffold is
the most promising avenue for total replacement because the collagenous framework is
already in the natural orientation allowing for proper cellular differentiation and
morphology. Proper differentiation and morphology allow the tissue to readily resume
the biochemical functions of the natural tissue. The natural orientation is also beneficial
in maintaining the natural mechanical properties of the tissue within the joint.
Supplemented with collagen crosslinking, the xenograft tissue based scaffold would be
more than be stable enough to allow for tissue regeneration of the host while maintaining
joint functionality. Further development of the decellularization process and antigen
removal would relieve the immunogenic stress normally placed on a xenograft and would
cement its place as the best treatment option for a total meniscus replacement.
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CHAPTER II
RESEARCH
Introduction
The previous chapter established that a xenograft tissue based meniscus scaffold,
coupled with a partial or full meniscectomy, is the most promising solution for damaged
meniscus repair. The purpose of this research was to provide a proof of concept that a
viable decellularized meniscus xenograft scaffold implant can be produced to fill this
demand. The first challenge of developing a xenograft meniscus scaffold implant was
first and foremost, antigen removal. Removing antigens, which would cause a host
immune response and transplant rejection, is paramount to the success of the concept.
Secondly, because a meniscus provides such a crucial role in locomotion, acting as the
shock absorber and friction reducer in the knee, the biomechanical properties of the tissue
are also critical to the overall functionality of the transplant. The design of this proof of
concept was comprised of three experiments; the first experiment is to develop an antigen
removal protocol, and the last two experiments explore the understanding and
manipulation of the biomechanical properties of the tissue.
The goal of the first, and most important experiment, was the development of an
optimal antigen removal protocol. Current research has shown that antigen removal
within thick connective tissue, like meniscus, to acceptable levels of immunotolerance is
possible.1 However, these published protocols are time consuming, expensive, and/or
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damaging to the structural properties of the tissue, making these current protocols not
conducive to expanding the research on xenograft meniscus transplants. This study
proposed modifying a less invasive antigen removal protocol that uses SDS for antigen
removal, originally designed and proven effective for articular cartilage,2 to create a
faster and more cost-efficient method to create a decellularized scaffold. These less harsh
conditions will, in theory, maintain the structural integrity of the graft, while also
reducing production time and cost.
The second experiment investigated the biochemical and biomechanical
differences between the native meniscus tissue and the decellularized meniscus scaffold.
This experiment was vital because any antigen removal protocol has some effect on the
biochemical and biomechanical properties of the tissue. First, a more in depth study on
the effectiveness of the antigen removal protocol was conducted to include DNA and
GAG removal. GAG performs a critical role in shock absorbance through water retention
in the native tissue, and although it would be beneficial to maintain, it is mildly
immunogenic and is almost impossible to retain during efficient antigen removal.
However, one benefit of GAG removal is that it increases porosity in the scaffold that
will ease cellular migration into the scaffold. Collagen content was also assessed to
determine if the antigen removal protocol was also removing collagen from the tissue. If
collagen was being removed, it would indicate that the structural integrity of the tissue
was being compromised by the antigen removal. Compression and tensile testing was
performed on both the fresh native tissue and the decellularized scaffold to determine if
the decellularized tissue would be able to withstand normal loading associated with
weight bearing and gait. Comparing the mechanical properties of the two tissues will
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help determine if the tissue would be too rigid and inflexible such that it would damage
the femoral articular cartilage or overall knee functionality. Comparing the biochemical
and biomechanical analyses of the two tissues will give a greater understanding of the
antigen removal process and serve as a spring board for further research.
The third experiment was designed to investigate the feasibility of further treating
the tissue via collagen crosslinking. Crosslinking the tissue could be an important aspect
of the development of the xenograft as a whole because it inhibits rapid enzymatic
degradation of the scaffold. In terms of biomechanics, crosslinking would also be
expected to restore some of the compressive resistance lost as a result of the GAG
removal. Crosslinking may also increase tensile stiffness, which might be an undesirable
side effect if antigen removal alone increases the tensile modulus. By being able to
consciously adapt the biomechanical properties of the xenograft, the transplant can be
engineered to match the specifications of the native host tissue. The goal of this
experiment was to determine the effect of various chemical crosslinkers, genipin and
EGCG, and their concentrations on the xenograft meniscus. Genipin and EGCG were
chosen for this experiment due to their low cytotoxicity and their proven collagen
crosslinking ability in literature.2,3 Additionally, due to the fact that menisci are large and
dense pieces of connective tissue, and previous research on crosslinking similar tissues,
such as tendons and ligaments, has shown thorough crosslinking of these tissues to be
difficult,4 two pre-crosslinking treatment protocols were designed to increase the
permeability of the crosslinkers into the meniscus tissue. The two pre-crosslinking
treatment protocols developed for this experiment are freeze drying the tissue before
crosslinking and soaking the tissue in a super saturated saline solution, then freeze drying
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the tissue before crosslinking. Both pre-crosslinking treatment protocols utilize osmotic
gradients to attempt to increase permeability of the aqueous crosslinkers to the inner most
portions of the meniscus.
The goal of this study is that the data collected from the three experiments will
build a strong foundation of fundamental knowledge about the development and
biomechanical behaviors of a decellularized xenograft meniscus scaffold. It is
hypothesized that an effective and more efficient antigen removal protocol can be
developed to create a xenograft meniscus replacement that is comparable to current
protocols, and that the decellularized scaffold created from that protocol can
bioengineered to mimic native tissue in its mechanical properties.
Experimental Methods
Experiment 1: Antigen Removal Protocol
The original antigen removal protocol, Protocol 1 (P1), was adapted from the
antigen removal procedure used for osteochondral bone plugs fused with articular
cartilage taken from the articular surfaces of the tibia and femur inside the knee joint.2
Articular cartilage is much thinner than meniscus tissue, so the original protocol was
modified to penetrate the thicker tissue. The sequential protocols, Protocol 2 (P2) and
Protocol 3 (P3), made adjustments to soaking times and additional antigen removal steps
were added or removed to optimize the procedure. To assess antigen removal, DNA
content was measured in 39 total samples from 13 different menisci for P1, P2, and the
FTC each, and 24 total samples from 8 menisci for P3 and SP each.

42

Stabile Protocol
The Stabile Protocol (SP) is a well-established protocol that was used to compare
the protocol developed in this research. Eight menisci were placed in distilled
DNase/RNase-free water in a shaker at 200rpm at 37˚C for 48 hours to lyse the cells.
Then the menisci were treated with a 0.05% trypsin-ethylenediaminetetraacetic acid on
the shaker for 24 hours. The menisci were then treated with Dulbucco’s modified
Eagle’s medium with high glucose, 10% fetal bovine serum, and 1% antibioticantimycotic solution for 24 hours to neutralize the trypsin. The menisci were then treated
with a 2% aqueous Triton X-100 and 1.5% peracetic acid solution for 48 hours. The
meniscus were then washed in dH2O once for an hour and then for 72 hours, changing the
water every 24 hours. Finally, the menisci were washed in PBS for 24 hours.
Protocol 1
Thirteen menisci were cleaned after extraction in PBS twice for one hour, then in
10% hydrogen peroxide for one hour, and finally in dH20 for an hour. The menisci were
then treated with a 2.0% SDS, 10mM Tris-HCl (pH 7.6), 1mM PMSF, 5mM MgCl2,
0.5mM CaCl2, 0.5 mg/ml DNase I, 0.05mg/ml RNase, 1% antibiotic-antimycotic solution
for 48 hours, changing the solution every 24 hours. The menisci were then washed in
10mM Tris-HCl (pH 7.6) for 90 minutes and then twice in dH2O for 30 minutes. All
treatments were performed in a shaker at 37˚C.
Protocol 2
The second protocol adaptation was designed to maximize the decellularization
potential by including several different antigen removal steps. The protocol further
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increased treatment times in certain solutions, added EtOH and hyaluronidase treatments,
and the menisci were sonicated for 10 minutes after each step of the protocol. Thirteen
menisci were cleaned after extraction twice in PBS for one hour, a 10% hydrogen
peroxide solution for 8 hours, and then degreased in EtOH for three hours. The menisci
were treated with a 0.2% hyaluronidase, 10 mM Tris-HCl (pH 7.6) solution for 48 hours,
changing the solution every 24 hours. The menisci were then treated with a 2.0% SDS,
10mM Tris-HCl (pH 7.6), 1% antibiotic-antimycotic solution for 72 hours, changing the
solution every 24 hours. The menisci were then treated in a 10mM Tris-HCl (pH 7.6),
1mM PMSF, 5mM MgCl2, 0.5 mM CaCl2, 0.5mg/ml DNase I, 0.05mg/ml RNase, 1%
antibiotic-antimycotic solution for 48 hours, changing the solution every 24 hours.
Finally the menisci were washed in dH2O twice for 30 minutes. All treatments were
performed in a shaker at 37˚C.
Protocol 3
The third and final protocol was designed to use a hypotonic osmotic gradient to
induce cell lysis in addition to the SDS detergent. Eight menisci were cleaned after
extraction twice in PBS for one hour, then in 10% hydrogen peroxide for 8 hours, and
finally twice in dH20 for one hour. The cells were lysed in dH20 for 48 hours, changing
solution every 24 hours. Then the menisci were treated in a 2.0% SDS, 10mM Tris-HCl
(pH 7.6), 1mM PMSF, 5mM MgCl2, 0.5mM CaCl2, 0.5mg/ml DNase I, 0.05mg/ml
RNase, 1% antibiotic-antimycotic solution for 48 hours, changing the solution every 24
hours. The menisci were then washed in dH2O twice for one hour and then overnight in
a large volume of dH2O for 8 hours. All treatments were performed in a shaker at 37˚C.
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This protocol was found to be superior to all of the previous protocols and was used for
all subsequent tests for the decellularized xenografts.
Experiment 2: Biochemical and Biomechanical Analysis of Protocol 3
A vertical cross section was taken from a random meniscus from both the FTC
and P3 test groups and was plated onto a slide. The slide was stained with Safranin-O
and was analyzed using light microscopy. Biochemical analysis was performed to
quantify antigen removal with DNA content and GAG content, and to ensure that
collagen was not being removed during the antigen removal protocol. Removal of
collagen would indicate a loss of structural integrity and function. Biochemical analysis
was performed on 12 total samples from the body of 6 FTC menisci and 12 total samples
from 6 menisci treated with P3.
Papain Digestion
Meniscus samples had to be digested in papain in order to perform the
biochemical analysis of DNA content, GAG content, and collagen content. The same
samples of papain digested menisci were used to complete all three biochemical analysis
tests. The papain digestion buffer is a 10mM cysteine solution in PBE buffer with 50μL
of papain. Samples are digested in papain solution overnight at 60˚C in a water bath and
then spun at 10,000rpm for 3 minutes. The supernatant was then be used for various
biochemical analysis.
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Biochemical Analysis
DNA content, GAG content, and collagen content analyses were performed on the
papain digested samples as previously described, with minor modifications to
accommodate the larger sample sizes.2
Compression Testing
A stress-relaxation compression test was performed to determine the change in
biomechanical properties of the decellularized samples compared to the control meniscus
samples, with regards to compressive forces. The compression testing was performed
using a Mach 1 machine. A total of 24 samples collected from both 4 FTC menisci and 4
P3 menisci using a deli slicer to take even horizontal cross sections of approximately
3mm thickness, and then a 4mm biopsy punch was used to punch out round disks from
the cross sections.
The test was performed with the sample being submerged in a bath of PBS
between smooth impermeable plates. The thickness of each disk was determined by
applying an initial load of 10 gf and measuring the distance between compression plate
and the base of the bath. A 5% ramp strain was calculated from the thickness of each
sample. Five compressions were applied to the sample, each increasing by the 5% strain,
from 5%-25%, allowing the tissue to relax in between ramps until the slope of the values,
measured at 15 second intervals, was less than 0.2500 gf/min.
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Figure 2.1

Stress-Relaxation Compression Test: Five compressions, increasing in 5%
increments, allowing for the tissue to relax in between intervals.

The peak stress modulus, also referred to as the instantaneous modulus, and
equilibrium stress moduli were calculated by plotting the 5 peak stress points, depicted in
Figure 2.1 in red, and 5 equilibrium stress points, depicted in Figure 2.1 in green, against
strain and determining the slopes of the respective stress vs strain plots.

Figure 2.2

Stress vs strain graph to calculate the instantaneous and equilibrium moduli
from compression data.
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Tensile Testing
A tensile test was performed to determine the change in tensile properties of the
decellularized samples compared to the control meniscus sample. Tensile testing was
performed using an MTI-2K machine. Samples were collected from both control and
decellularized meniscus using a deli slicer to take even horizontal cross sections, then a
custom designed and built stamp was used to punch out dumbbell shaped sections of the
tissue. The dimensions of the stamp are 9mm wide at the ends, 3mm wide in the middle
section, with a gauge length of 18mm. The overall length of the sample was determined
by the size of the meniscus, and it varied for each sample. Three thickness measurements
were taken were taken at various points of the middle gauge length with digital calipers
to calculate an average thickness for the sample.

Figure 2.3

The custom made tissue punch and the resulting dumbbell shaped tissue
removed from the original meniscus tissue.

The dumbbell shaped tissue’s was secured at both ends into a set of clamps
attached to a 200N load cell and the MTI-2K machine. A 5N preload was applied to the
tissue to remove any slack in the tissue before testing. The sample was pulled at 5
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mm/min until failure. Only samples where the failure occurred in the middle portion of
the tissue were kept, any failure resulting from the grips was discarded.

Figure 2.4

Tensile Testing Setup: The sample was clamped in place at both ends on
the MTI-2K machine (left). An excepted test with structural failure
occurring in the middle portion of the tissue sample (right).

Strain was calculated by dividing displacement by the gauge length of the tissue
sample. Stress was calculated by dividing load by the average thickness of the tissue
sample. Stress vs strain was plotted and the modulus of elasticity, which was defined for
this experiment to be the maximum slope in the elastic region of the graph, was
determined.

Figure 2.5

Stress vs Strain Graph: The stiffness modulus was defined as the
maximum slope of the elastic region.
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The ultimate tensile stress, strain at failure, and energy absorbed until failure were
also determined and/or calculated from their corresponding points on the graph.
Experiment 3: Crosslinking Assessment and Permeability
Decellularized menisci were treated with two different nontoxic crosslinkers,
genipin and epigallocatechin gallate (EGCG). Three concentrations of genipin were
tested to produce a wide range in the degree of crosslinking, based on previous research
on articular cartilage,2 0.2%, 0.04%, and 0.008%, and one concentration, 1%, of EGCG
was tested. Eleven menisci were randomly assigned to the 5 different treatment methods,
with two menisci for each of the four crosslinking treatments and 3 mensici assigned as
the fresh tissue controls. The menisci were treated with the appropriate solutions for 72
hours, changing the solution every 24 hours. Samples were then taken from each menisci
to determine the permeability of the various crosslinkers and concentrations. Vertical
cross sections were taken from each sample and a 4.0mm biopsy punch was used to
punch out the centermost portion of the cross section.
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Figure 2.6

Vertical cross section of a meniscus with the inner portion removed. Both
portions are assed for percent crosslinking to determine permeability.

The difference in crosslinking percentage between the outer portion and inner
portion was then calculated to determine the permeability of the crosslinker used.
Crosslinking Assessment
The percentage of crosslinking in a sample was determined using a Ninhydrin
Assay, which indicates the amount of free amino groups. Two solutions were prepared,
the first solution was created by adding 1.05g citric acid, 10mL (1.0M) aqueous NaOH,
and 0.04g SnCl2⦁2H20 and then adding dH2O until 25mL. The second solution was
created by adding 1g ninhydrin to 25mL of 2-methoxyethanol. The two solutions were
blended and stirred for 45 minutes to complete the ninhyrdin solution.
Test samples were freeze-dryed for 24 hours and weighed to determine their dry
weigh. The sample was then placed in a tube with 3mL of ninhydrin solution in a 100˚C
water bath for activation four minutes, a time that was determined using a positive
control sample as a reference. The tubes were cooled in a cool water bath and then were
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read with a microplate spectrophometer at 570nm. The degree of crosslinking was
calculated as previous described in previous research.3
Crosslinking Permeability
Two adaptations to the administration of the crosslinking treatment were tested to
attempt to increase permeability. Three groups of 10 decellularized menisci were subject
to different pretreatment conditions before all of the groups were individually treated
with a 0.04% genipin solution for 72 hours, changing the solution every 24 hours. The
first group of decellularized menisci was freeze-dried for 24 hours in a vacuum prior to
the crosslinking treatment. The second group of decellularized menisci was treated in a
super saturated 28.1% NaCl solution for 72 hours, changing the solution every 24 hours,
and then freeze-dried for 24 hours in a vacuum prior to crosslinking. The control group
of decellularized menisci was only treated with the crosslinking treatment. Samples were
then taken from each meniscus in each group to determine if there was a difference in
permeability due to the different pre-crosslinking treatments. Vertical cross sections
were taken from each sample and a 4mm biopsy punch was used to punch out the
centermost portion of the cross section. Differences in crosslinking percentages between
the outer and inner portions were calculated and assessed.
Results
Experiment 1: Antigen Removal Protocol
The average DNA content for the FTC, P1, P2, P3, and SP, in ng DNA/mg, were
calculated to be 26.62 ± 12.91, 30.57 ± 9.70, 28.83 ± 7.42, 18.05 ± 4.61, and 17.53 ±
9.31, respectfully, as can be seen in Table 2.2. Statistical analysis was performed using
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SAS calculated the critical value of t to be 1.97509 with a least significant difference of
4.7773. P1 and P2 were not significantly different from FTC, and are therefore not an
effective antigen removal protocol. P3 was found to have significantly lower average
DNA content than FTC and was also not significantly different than SP.
Table 2.1

DNA Content in ng DNA/mg of three antigen removal protocols (P1, P2,
P3), a fresh tissue control (FTC), and the Stabile antigen removal protocol
(SP).
FTC

P1

P2

P3

SP

Average DNA Content
(ng DNA/mg)

26.62

30.57

28.83

18.05

17.53

Standard Deviation

12.91

9.70

7.42

4.61

9.31

Figure 2.7

DNA content in ng DNA/mg for the three antigen removal protocols (P1,
P2, P3) a fresh tissue control (FTC) and the Stabile antigen removal
protocol (SP).
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Table 2.2

T-Tests (LSD) for DNA Content in ng DNA/mg from SAS Output.
T Tests (LSD) for DNA Content
t Grouping Mean N PROTOCOL
A
30.574 37
P1
A
A
28.834 39
P2
A
A
26.625 39
FTC
B
18.045 24
P3
B
B
17.525 24
SP

Experiment 2: Biochemical and Biomechanical Analysis of Protocol 3
Microscopy
Under 20x magnification, the Safranin-O stained slide, clearly shows evidence of
successful decellularization. As can be seen in Figure 2.8, at 20x magnification there is
strong evidence that P3 is an effective decellularization protocol.
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Figure 2.8

20x image of Safranin-O stained vertical cross section of FTC (left) and
P3(right) meniscus. A) FTC femoral surface B) P3 femoral surface C) FTC
midsection D) P3 midsection

The darkest staining regions of the FTC are the cell nuclei of fibrochondrocytes
habiting their lacunae in the tissue. The P3 meniscus clearly shows an overall absence of
these dark staining areas and empty lacunae. The P3 meniscus also shows a significant
reduction in the amount of GAG and ECM, the red staining portion of the FTC. This
effect can be better seen in Figure 2.8, a 5x magnification mosaic image of the entire
cross section created using ImageJ.
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Figure 2.9

5x magnification compiled mosaic of the FTC (left) and P3 (right) menisci.
A) FTC meniscus B) P3 meniscus

The outside portions of the menisci appear to be completely devoid of GAG and
only a small residual amount is leftover in the inner portion. There is a stark difference in
the overall amount of GAG in the P3 meniscus compared to the FTC meniscus, which
provides evidence to the antigen removal effectiveness of P3.
DNA Analysis
The average DNA content of the FTC was calculated to be 14.2926 ng DNA/mg
and the P3 average DNA content was calculated to 7.27355 ± 0.47699 ng DNA/mg. A
two sample t-Test assuming unequal variances with a hypothesized mean difference of 0
at the significance level of α = 0.05 was performed on the data collected from the two
groups. Menisci treated with P3 were found to have a significantly lower average DNA
content than the FTC menisci with a p-value of 0.000225.
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Figure 2.10

DNA Content Comparison between FTC and P3. Menisci treated using P3
have a significantly lower DNA Content (ng DNA/mg) than FTC.
GAG Analysis

Menisci treated with P3 had 0.7787 μg GAG/ mg of sample compared to the
0.199667 μg GAG/mg of sample of the FTC menisci. A two sample t-Test assuming
unequal variances with a hypothesized mean difference of 0, at the significance level of
α=0.05 was performed on the data collected from the two groups. The mean GAG
content of menisci treated with P3 was significantly lower than the FTC, with a p-value
of 0.001846. The data supports the significant difference seen in the Safranin-O slides of
the FTC and P3.
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Figure 2.11

GAG Content Analysis between FTC and P3.
Collagen Content

The Safranin-O stained slide was viewed under cross polarization in order to see
the orientation of the collagen bundles of the P3 meniscus. The collagen bundles in the
P3 menisci, seen in both 5x and 20x magnification, are not disturbed by the treatment and
maintain a tight bundle and natural orientation.
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Figure 2.12

P3 meniscus cross section under cross polarization to show collagen bundle
structure and orientation.

The average collagen content of the FTC menisci was calculated to be 6.563657 ±
1.779202 μg collagen/mg and the P3 menisci was 6.268484 ± 1.8728 μg collagen/mg. A
two sample t-Test assuming unequal variances with a hypothesized mean difference of 0,
at the significance level of α=0.05 was performed on the data collected from the two
groups.

Figure 2.13

Collagen Content Analysis between FTC and P3.
Compression Testing

The instantaneous modulus for the FTC was calculated to be 2.5523 MPa and the
equilibrium modulus was calculated to be 0.0529 MPa. The instantaneous modulus for
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P3 menisci was calculated to be 0.8019 MPa and the equilibrium modulus was 0.1013
MPa. A two sample t-Test assuming unequal variances with a hypothesized mean
difference of 0, at the significance level of α = 0.05 was performed for the instantaneous
modulus and equilibrium modulus independently. The p-value for the instantaneous
modulus, as seen in Table 2.4, was calculated to be 0.0013 and the p-value for the
equilibrium modulus was 0.0036.
Table 2.3

Average Compression Moduli Comparison between FTC and P3.
Mean Compression Moduli (MPa)
FTC
P3
Instantaneous Modulus
2.5523
0.8019
P(T<=t) two-tail
Equilibrium Modulus
P(T<=t) two-tail

0.0013
0.0529
0.0036

0.1013

Both the instantaneous modulus and the equilibrium modulus for the FTC menisci
were significantly higher than the P3 menisci.
Tensile Testing
The FTC menisci were found to have an average tensile modulus of 29.6519
MPa, average ultimate tensile stress of 7.3234 MPa, average strain at failure was 0.3534,
and the energy absorbed was calculated to be 1.1856 J·m-3·104. The P3 menisci were
found to have an average tensile modulus of 72.3724 MPa, average ultimate tensile stress
of 12.1215 MPa, average strain at failure was 0.2256, and the energy absorbed was
calculated to be 1.3380 J·m-3·104.
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Table 2.4

Comparison of tensile properties of FTC and P3 calculated from testing
data.

FTC
P3
P(T<=t) two-tail

Tensile
Modulus
(MPa)
29.6519
72.3724
0.00003

Ultimate tensile
stress (MPa)

Strain at
Failure

Energy Absorbed
(J·m-3·104)

7.3234
12.1215
0.00071

0.3534
0.2256
0.00003

1.1856
1.3380
0.39495

The P3 menisci had a significantly higher tensile modulus and ultimate tensile
stress than the FTC menisci. The P3 had a significantly lower strain at failure than the
FTC menisci. There was no significant difference in the energy absorbed by the P3 and
FTC menisci.
Experiment 3: Crosslinking Assessment and Permeability
Crosslinking Assessment
A vertical cross section was taken at random from each of the four treatment
groups. Pigmentation is a side effect of both genipin and EGCG and it can be used as an
estimate for degree of crosslinking, with more intensely pigmented regions having higher
degrees of crosslinking. There was evidence that the permeability of genipin is
determined by concentration, as the inner portions of the menisci proceed to get lighter as
the dilution was increased.

Figure 2.14

Cross sections of four different crosslinking treatments. A) 0.2% Genipin
B) 0.04% Genipin C) 0.008% Genipin D) 1% EGCG.
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The degree of crosslinking, shown in Figure 2.15, was compared for each
treatment. Statistical analysis on the values for the degree of crosslinking was computed
using SAS. The critical value of t was found to be 2.08596 with a least significant
difference of 23.152 at the significance level of α=0.05. The values from Table 2.6 show
that the outer portion of the 0.2% genipin treatment had the highest degree of
crosslinking with 78.02%. There was no significant difference between 0.2% genipin
and the 1% EGCG treatment with regards to degree of crosslinking in the inner portion of
the menisci, and both had significantly higher degree of crosslinking in the inner portion
than 0.04% and 0.008% genipin.

Figure 2.15

The permeability of genipin and EGCG as a crosslinking agent with
regards to degree of crosslinking for menisci.
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Table 2.5

T-Test (LSD) for degree of crosslinking for four differently crosslinking
treatments.
t-Test (LSD) for Degree of Crosslinking
t Grouping Mean Treatment and Portion
A
78.02
0.2% Genipin Outer
A
B
A
60.82
1% EGCG Inner
B
B
53.98
1% EGCG Outer
B
B
47.74
0.2% Genipin Inner
C
24.47
0.04% Genipin Outer
C
D
C
19.51
0.008% Genipin Outer
D
C
D
C
3.34
0.04% Genipin Inner
D
D
0.00
0.008% Genipin Inner

The 1% EGCG had the most permeability as a crosslinker, despite not being
indicated by a color change due to crosslinking. This can be inferred as it had only a
6.84% difference in the degree of crosslinking between the inner and outer portions,
which was the smallest of all four treatments. The permeability of genipin decreased
rapidly with dilution, with only 3.34% crosslinking at 0.04% genipin and 0.00%
crosslinking at 0.008% genipin. However, after the initial significant decrease in the
degree of crosslinking of the outer portion caused by genipin due to dilution from 0.2% to
0.04%, there was not a significant change in the degree of crosslinking as genipin was
further diluted to 0.008%.
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Crosslinking Permeability
The average degree of crosslinking for control meniscus was 70.11% for the outer
portion and 36.78% for the inner portion. The freeze-dry treatment had a degree of
crosslinking of 68.64% for the outer portion and 37.61% for the inner portion. The salt
solution bath and freezes-dry treatment had a 72.35% degree of crosslinking on the outer
portion and a 31.07% degree of crosslinking on the inner portion.

Figure 2.16

Degree of Crosslinking results for the freezes-dry, the salt solution bath and
freeze-dry, and control pretreatments for genipin crosslinking.

A statistical analysis of the data was conducted using SAS at the significance
level of α=0.05, the critical value of t was calculated to 2.00488 with a least significant
difference of 0.0973. The outer portions had a significantly higher degree of crosslinking
compared to the inner portions. However, there was no significant difference between
pretreatment protocols with either the out or the inner segments.
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Table 2.6

T-Tests (LSD) for the Degree of Crosslinking of Pretreatment Protocols.
T Tests (LSD) for Degree of Crosslinking of
Pretreatment Protocols
t Grouping
Mean
TRT
A
0.72347 Salted+Freeze Dry (outer)
A
A
0.70110
Control (outer)
A
A
0.68643
Freeze Dry (outer)
B
0.37607
Freeze Dry (inner)
B
B
0.36775
Control (inner)
B
B
0.31069 Salted+Freeze Dry (inner)

Discussion
The goal of this study was to provide strong evidence to the proof of concept for
the ability to produce a decellularized xenograft meniscus implant that could be used for
a partial or full meniscectomy. It was hypothesized that an effective and more efficient
antigen removal protocol can be developed that is comparable to current protocols, and
that the decellularized scaffold created from that protocol can bioengineered to mimic
native tissue in its mechanical properties. This study provides evidence that there is no
significant difference between P3 and SP, a currently published and established protocol,
with regards to DNA removal. In terms of production time, SP requires 240 hours (10
days) to complete, while P3 requires less than half, 49.17%, of that time at 118 hours (4
days, 22 hours) to fully process the tissue. The development of P3 supports the initial
portion of the hypothesis that an antigen protocol can be developed that is not
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significantly different from a well-established antigen removal protocol, but be more
efficient in terms of production time and material consumed in production.
The antigen removal analysis showed that P3 significantly lowered the DNA and
GAG content in the meniscus receiving the treatment, however, as can be seen in the test
data and microscopy, there was residual porcine DNA and GAG content in the treated
meniscus. There is currently no published data on the threshold of immunotolerance of a
host to these residual antigens. Menisci in general are not very vascular tissues, so the
likelihood of an immune response would be very low. The fact that P3 was not
significantly different from SP in terms of antigen removal is promising, but further
testing would need to be developed to ensure that the residual porcine material falls
below the immune threshold so a transplant would not be rejected.
The relationships observed in the compression and tensile moduli of the FTC and
P3 menisci support previous literature on decellularized collagen scaffolds.5
Understanding the degree in which these values changes helps direct further research into
the bioengineering of the tissue to the desired specifications. Further research into the
coefficient of friction differences in the native tissue and the decellularized tissue would
also be beneficial.
The third experiment provided insight into the crosslinking effects, should it be
needed to treat a would-be implant. A dose of 0.2% genipin, which is relatively low,
proved to induce the greatest degree of crosslinking of the meniscus tissue; however, its
low permeability prevented an even degree of crosslinking throughout the tissue. The
permeability of EGCG was far superior, which could be due to a different mechanism of
crosslinkage than genipin.3 Further research into the physical requires of the implant
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would need to be established, particularly if the tissue must have an even level of
crosslinking throughout or if a highly crosslinked outer portion with a softer inner portion
would act as a better shock absorber. Research that could test the various crosslinkers in
situ could be designed using this research’s findings.
In conclusion, this study has provided strong evidence to a proof of concept that a
decellularized xenograft meniscus scaffold can be effectively and efficiently produced
and that it can be modified via collagen crosslinking to fit the specifications needed for it
to be used as an implant for a partial or full meniscectomy.
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